Loading clinical trials...
Loading clinical trials...
A Prospective, Open-Label, Single-Arm Study of Iparomlimab and Toripalimab Plus Nab-Paclitaxel With or Without Bevacizumab in Recurrent/Metastatic Cervical Cancer Progressed on Anti-PD-(L)1 Therapy
Conditions
Interventions
Iparomlimab and Tuvonralimab (QL1706) + Nab-Paclitaxelwith or without Bevacizumab
Start Date
October 15, 2025
Primary Completion Date
August 30, 2027
Completion Date
December 30, 2027
Last Updated
September 22, 2025
NCT06238635
NCT04380805
NCT02164461
NCT05715840
NCT04943627
NCT01846520
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions